CD79B and diffuse large B-cell lymphoma: CD5+ diffuse large B-cell lymphoma (DLBCL) is a rare subtype with aggressive clinical behavior characterized by a high frequency of MYD88L265P mutations and CD79B mutations associated with persistent activation of the B-cell receptor (BCR) signaling pathway (13).